Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Shareholder Meeting (November 2023)
25 slides from Argenica Therapeutics's shareholder meeting presentation, November 2023
Slide 1: Argenica Therapeutics AGM Presentation
ARGENICA THERAPEUTICS AGM PRESENTATION ASX: AGN MANAGING DIRECTOR PRESENTATION NOVEMBER 2023 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Neuroprotective Opportunity & Our Encouraging Results to Date
NEUROPROTECTIVE ARGENICA THERAPEUTICS OPPORTUNITY & OUR ENCOURAGING RESULTS TO DATE 3 www.argenica.com.au
Slide 4: Breakthrough Mission
BREAKTHROUGH MISSION NEUROPROTECTIVE Commercialise breakthrough neuroprotective treatments that minimise SOLUTIONS TO REDUCE brain damage and foster recovery BRAIN DAMAGE ARGENICA THERAPEUTICS VISION Achieve global recognition as the most valuable neuroprotective company, and redefine the standard o
Slide 5: The Opportunity in Front of Us
THE OPPORTUNITY IN FRONT OF US NEUROPROTECTIVE TREATMENTS ARE A NEW FRONTIER IN MEDICINE… There are no There is marketed drugs increasing interest that protect the ARGENICA THERAPEUTICS in neuroprotection brain after stroke from big pharma Our drug ARG-007 Untapped aims to fill this commercial urgen
Slide 6: Argenica Board
ARGENICA BOARD ARGENICA THERAPEUTICS Dianne Angus Dr Liz Dallimore Geoff Pocock Liddy McCall Terry Budge Non-Executive Chairman Managing Director Non-Executive Director Non-Executive Director Non-Executive Director • Senior executive within the • Over 20 years' experience in • 20 years’ experience i
Slide 7: Our Lead Drug Candidate
OUR LEAD DRUG CANDIDATE DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Efficacy Safety / Tox STROKE ABOUT ARG-007 Damage to the brain from interruption of its blood supply Cationic poly-arginine peptide HIE ARGENICA THERAPEUTICS Hypoxic ischemic encephalopathy (HIE) Multiple mechanisms of action dev
Slide 8: Potential of ARG-007
POTENTIAL OF ARG-007 MAIN INDICATIONS ADDRESSABLE MARKET SUMMARY OF RESULTS TO DATE STROKE USD$12bn 66% reduction 70% reduction by 20301 in Brain Tissue Death 24 hours after stroke in Brain Tissue Death 28 Days after stroke 1. Coherent Market Insights Report – Acute Ischemic Stroke (AIS) Market Anal
Slide 9: Enhancing Stroke Recovery with ARG-007
ENHANCING ARGENICA THERAPEUTICS STROKE RECOVERY WITH ARG-007 9 www.argenica.com.au
Slide 10: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS ONE IN FOUR ONLY 10% 1.9 MILLION people will suffer a will recover almost brain cells are attacked each stroke in their lifetime1 completely, due to the extent minute during a stroke2 o
Slide 11: Ischemic Stroke: How ARG-007 Works in Stroke
ISCHEMIC STROKE EXAMPLE HOW ARG-007 WORKS IN STROKE ARGENICA THERAPEUTICS INITIAL INFARCTION SETS OFF A CASCADE OF CELL DEATH THAT WILL CONTINUE SPREADING FROM LOCATION ARG-007 STOPS THE CASCADE OF CELL DEATH & PROVIDES A PROTECTION BARRIER AROUND ITHE INITIAL INFARCTION 11 www.argenica.com.au ARG-0
Slide 12: Multiple Mechanisms of Action
MULTIPLE TOXIC EVENT ARG-007 Represents where ARG-007 MECHANISMS significantly impacts activity OF ACTION: TARGETS CELL TOXICITY ARGENICA THERAPEUTICS Reduces calcium influx Preserves mitochondrial membrane potential NMDA (NR2B) downregulation Reduces GFAP and IL-6 expression Reduces MMP9 activation
Slide 13: Implications for Stroke Patients
IMPLICATIONS FOR STROKE PATIENTS REDUCTION IN REDUCTION IN CELL DEATH RECOVERY TIME OPTIONS FOR ARG-007 ADMINISTRATION ARGENICA THERAPEUTICS PATIENT HAS PATIENT IN ARRIVES AT DIAGNOSE TREATMENT AMBULANCE HOSPITAL STROKE TYPE PLAN REHAB BEGINS A STROKE Point of care intervention Alternatively, can be
Slide 14: Encouraging Stroke Results to Date
ENCOURAGING STROKE RESULTS TO DATE SUCCESSFUL 28 PHASE 1 (HUMAN Days after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE FIE
Slide 15: Phase 2 Clinical Trial in Stroke
PHASE 2 CLINICAL TRIAL IN STROKE NEAR TERM Q3 Q4 Q1 Q2 OVERVIEW TIMELINE CY23 CY23 CY24 CY24 Up to 10 Australian hospitals recruiting up Pre-IND FDA meeting to 92 patients ARGENICA THERAPEUTICS Ethics approval Double-blinded, randomised, placebo-controlled study Hospital site start-up ARG-007 will b
Slide 16: The Opportunity for ARG-007 in Other Indications
THE OPPORTUNITY ARGENICA THERAPEUTICS FOR ARG-007 IN OTHER INDICATIONS 16 www.argenica.com.au
Slide 17: ARG-007 Potential in HIE
ARG-007 POTENTIAL IN HIE TOTAL BRAIN INJURY AT 4 WEEK POST HIE WITH ARG-007 TREATMENT OR ARG-007 WITH STANDARD OF CARE HYPOTHERMIA3 HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE) ARGENICA THERAPEUTICS HIE occurs in 1.5 to 2.5 births per 10001 Current standard of care is hypothermia Awarded A$2.5m grant to a
Slide 18: FDA Has Granted ODD Status for HIE
FDA HAS GRANTED ODD STATUS FOR HIE Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ARG-007 for the treatment of Hypoxic ARGENICA THERAPEUTICS Ischaemic Encephalopathy (HIE). ODD qualifies AGN for incentives including: • Tax credits for qualified clinical trials
Slide 19: ARG-007 Potential in TBI
ARG-007 POTENTIAL IN TBI ARG-007 SIGNIFICANTLY REDUCES NFH PROTEIN AND APP FOLLOWING TBI2 TRAUMATIC 2000 180 BRAIN 1800 160 51% 52% INJURY 1600 reduction reduction 140 1400 ARGENICA THERAPEUTICS 120 Density of NFH (mm2) Density of APP (mm2) 1200 100 1000 Estimated USD$18.6bn 80 market size by 20311
Slide 20: ARG-007 Potential in Alzheimer's Disease
ARG-007 POTENTIAL IN ALZHEIMER’S DISEASE BETA AMYLOID AGGREGATION 100 % Reduction in Beta Amyloid 90 Aggregation inhibition 80 65% 70 ALZHEIMER’S 60 reduction DISEASE 50 40 30 20 ARGENICA THERAPEUTICS 10 0 Vehicle 2.5µM 7.5µM 25µM SIGNIFICANT INHIBITION Alzheimer’s therapeutics ARG-007 (µM) OF NEURO
Slide 21: ARG-007 Targets Protein Aggregation
Amyloid-beta aggregation ARG-007 MULTIPLE MECHANISMS OF ACTION: TARGETS PROTEIN ARGENICA THERAPEUTICS AGGREGATION Tau protein aggregation ARG-007 reduces aggregation of key neurodegenerative proteins which cause disease progression: ARG-007 Reduces aggregation of beta amyloid Reduces aggregation of
Slide 22: We Had a Very Successful 2023
WE HAD A VERY SUCCESSFUL 2023 SUCCESSFUL PHASE 1 CLINICAL TRIAL ETHICS APPROVAL FOR PHASE 2 IN STROKE ARGENICA THERAPEUTICS SUCCESSFUL FDA PRE-IND MEETING FEEDBACK SECURED +$4M IN NON-DILUTIVE FUNDING ENCOURAGING PRE-CLINICAL ALZHEIMER’S DATA ADDITIONAL HIE DATA SHOWING EFFICACY FDA GRANTED ORPHAN D
Slide 23: 2024 Will Be Equally Exciting
2024 WILL BE EQUALLY EXCITING… Our core areas of focus will be: ARGENICA THERAPEUTICS Initiating our Phase 2 clinical trial in stroke patients Receiving initial patient safety data from Phase 2 Continuing our engagement with global pharmaceutical companies Completing all required pre-clinical studie
Slide 24: Key Company Metrics
KEY COMPANY METRICS $7.4M R&D REFUND RECEIVED Q4 +$4M CASH @ BANK1 +$2.09M NON-DILUTIVE GRANTS2 ARGENICA THERAPEUTICS 98.3M $42M FUNDED SHARES ON ISSUE MARKET CAP3 TO COMMENCE PHASE 2 1. Cash balance as @ 30 September 2023 2. Various ASX Announcements dated 20 January 2023, 22 March 2023, 30 March 2
Slide 25: Argenica Therapeutics Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 25 www.argenica.com.au
Argenica Therapeutics — Shareholder Meeting (November 2023) on 6ix